Small‐molecule inhibition of inflammatory β‐cell death. (4th September 2013)

• Record Type: Journal Article
• Authors: Lundh, M.; Scully, S. S.; Mandrup‐Poulsen, T.; Wagner, B. K.
• Is Part Of: Diabetes, obesity & metabolism. Volume 15(2013)Supplement 3
• Page Start: 176
• Page End: 184
• Publication Date: 2013-09-04
• Subjects: apoptosis -- glucolipotoxicity -- glucotoxicity -- inflammation -- lipotoxicity -- proinflammatory cytokines -- small‐molecules -- β‐cell; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.12158
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract : With the worldwide increase in diabetes prevalence there is a pressing unmet need for novel antidiabetic therapies. Insufficient insulin production due to impaired β‐cell function and apoptotic reduction of β‐cell mass is a common denominator in the pathogenesis of diabetes. Current treatments are directed at improving insulin sensitivity, and stimulating insulin secretion or replacing the hormone, but do not target progressive apoptotic β‐cell loss. Here we review the current development of small‐molecule inhibitors designed to rescue β‐cells from apoptosis. Several distinct classes of small molecules have been identified that protect β‐cells from inflammatory, oxidative and/or metabolically induced apoptosis. Although none of these have yet reached the clinic, β‐cell protective small molecules alone or in combination with current therapies provide exciting opportunities for the development of novel treatments for diabetes.